UCANACT
PrivateLast Round
Pre Seed
Sep 20, 2026
Total Funding Raised
$1.03M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
UCANACT operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was a Pre Seed round in September 2026.
UCANACT is a neurotechnology company that develops a device-agnostic brain-computer interface platform to enable communication and device control for individuals with severe motor disabilities.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI, NLP & Conversational AI
Business Model
B2B
Customer Profile
Services & Consulting, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
UCANACT Comparables
Compare UCANACT with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuralink | 70% | |
| Tether | 69% | |
| Paradromics | 68% |
For institutional investors. Book with your work email.
UCANACT Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
UCANACT Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LUMO Labs | Pre Seed |
| Netherlands Organization for Scientific Research | Grant |
| Utrecht Holdings | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2026
$918K round led by LUMO Labs and Utrecht Holdings.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 20, 2026
Ucanact secures $918K in Pre Seed funding led by LUMO Labs and Utrecht Holdings Seed Fund to develop a brain-computer interface that translates brain signals into computer actions and speech in Netherlands in Sep '26.
- is_developingSep 20, 2026
Ucanact is developing a BCI that will enable people with paralysis to communicate using brain signals; the Netherlands-based startup has secured €800,000 in pre-seed funding, and three clinical studies are validating the technology.
- is_developingSep 15, 2026
Ucanact is developing a brain-computer interface that translates brain signals into computer actions and speech to help people communicate and interact with the world around them in the Netherlands on Sep 15th '26.
For institutional investors. Book with your work email.
UCANACT Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about UCANACT's valuation, stock price, and market status.
Is UCANACT a public or private company?
UCANACT is a private company.
What is the current stock price of UCANACT?
UCANACT is a private company, so its shares have no public market price. Caplight tracks UCANACT's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is UCANACT worth (valuation)?
Valuation information for UCANACT is not publicly available.
Can I buy UCANACT stock?
UCANACT shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was UCANACT's last funding round?
UCANACT's most recent funding round was Pre Seed on September 20, 2026.
Who are the main investors in UCANACT?
Key investors in UCANACT include LUMO Labs, Utrecht Holdings.
Will UCANACT IPO soon?
No public IPO plans have been announced for UCANACT.
How can I track UCANACT secondary market activity?
Caplight tracks bids, offers, and trades in UCANACT's shares on secondary markets.